
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
The recent discussions surrounding Hvo (Hvivo Plc) on ADVFN reflect a deeply divided investor sentiment, primarily focused on executive share transactions and their implications for the stock's future. A notable point of contention is the chairman’s substantial share sale shortly after a trading update, which has led some investors, such as "sikhthetech," to label it as a significant red flag, suggesting insider knowledge may influence such decisions. The continued selling from both the CEO and chairman is seen by many as a bearish signal, leading to a prevailing atmosphere of skepticism. For instance, "sikhthetech" remarked, "The biggest red flag was the Chairman dumping all his shares just 4 working days after the July TU," indicating concerns over leadership decisions affecting investor confidence.
Financially, investors were spurred by a recent report from Shore Capital initiating coverage of Hvo with a bullish target price of 35p per share—more than double its current trading levels. However, the overall investor outlook seems cautious, reflecting fears of underperformance and declining stock prices, as indicated by "chica1" stating, "Mo selling has killed the share no matter what way you look at it." Additionally, sentiments like "If you haven't seen the tumble in the markets...you are blinkered" highlight worries about broader market conditions impacting Hvo's stock performance, leaving many investors unsettled despite the optimistic analyst rating. The juxtaposition of positive analyst forecasts against a backdrop of executive selling and broader market concerns poses a complex scenario for existing and potential investors in Hvo.
Show more
hVIVO Plc, a leading Contract Research Organisation specializing in human challenge clinical trials, has announced significant developments in recent weeks. On March 6, 2025, Yamin Khan, a director of the company, exercised 6,440,119 options under the Long Term Incentive Plan at £0.001 per share, subsequently selling 3,062,246 shares at 17p each to cover costs and tax obligations. This exercise indicates continued confidence in the company's growth trajectory as Mr. Khan retains a substantial stake in hVIVO.
Additionally, hVIVO has undertaken a strategic acquisition of Cryo-Store Limited, a provider of temperature-controlled storage solutions, for up to £3.2 million, which is expected to enhance its operational capabilities in biostorage. On the contracting side, the company secured a £2 million deal to progress a human metapneumovirus (hMPV) characterisation study, reflecting its ongoing commitment to advancing vaccine research in infectious and respiratory diseases. These developments highlight hVIVO's robust positioning in the CRO sector and its focus on expanding its service offerings and technological advancements.
Show more
interesting 2x18m sells. |
Adorling |
The meeting is up on Investor Meet Company website now. All very positive and clear and good answers to all the pressing questions and a very good outlook for this year. |
Cheers RA3 |
Ah the old “paid for shorting posts” angle. |
Don't think you added the 18m and 17.9m lots though... |
I hope all the naysayers who between them own sod all shares watched the InvestorMeet Presentation just now where Mo Khan CEO and Stephen Pinkerton CFO answered all questions in a straight forward way . Don’t let these naysayers on this board who are paid for their shorting posts blind you from a potential good investment opportunity especially at today’s price. |
Yawn yawn yawn - if you don’t have anything new to say then don’t say anything at all - just go away |
Protrader |
There you go, the chairman DID know more about the company than any II/PI. |
The dreaded H2 weighting ... |
The share price is sitting at the same level it was in September 2020.Just think about that for a minute. This truly is a traders share.So many opportunities to make money here over last 4 years. |
Hmmmm. Just goes to show institutions get it wrong sometimes. Not one of their best decisions. |
Agree malcolmz1 but surely it is inconceivable that Octopus didn’t ’make the call’ to get some comfort about the future before they bought another 1% at around 19p? |
Cathal must be so glad he sold out 50% higher. Someone at Octopus has some explaining to do. Oh, what a game this is. |
Anyone can buy businesses to increase revenue. To be fair thats what they said they were aiming at, they didn’t specify how, or whether they would overpay for a loss maker. |
And Cavendish at 35p so a 79% uplift from current share price |
Two brokers have repeated their 'buy' recommendations for shares in hVIVO PLC (AIM:HVO) in the wake of an announcement on a key acquisition and an update on trading.Peel Hunt has a target price of 34p, while Panmure Liberum's valuation is 24p (current price 19.08p).Earlier, the company said it had taken a big step towards its goal of reaching £100 million in revenue by 2028 with the acquisition of two clinical research units in Germany for £8.4 million (10 million) from Clinical Research Services Management (CRS). |
My wife had whooping cough last year and it sounded (and felt apparently) as if she was about to keel over; there’s a long period of coughing afterwards. She had some antibiotics that made her a bit high - spontaneously booked a weekend in Berlin and a PJ Harvey concert there we could go to. |
hxxps://www.regulati |
Pierre |
The fy2025 revenue guidance is £73m, £10m higher than fy2024. |
Imo there isn’t much difference from when CF was in charge. |
Type | Ordinary Share |
Share ISIN | GB00B9275X97 |
Sector | Pharmaceutical Preparations |
Bid Price | 16.00 |
Offer Price | 16.50 |
Open | 16.25 |
Shares Traded | 392,484 |
Last Trade | 16:35:11 |
Low - High | 16.25 - 16.25 |
Turnover | 56.04M |
Profit | 16.12M |
EPS - Basic | 0.0237 |
PE Ratio | 6.86 |
Market Cap | 109.54M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions